Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial.
By A. Lincoff, J. Bittl, Robert A. Harrington, F. Feit, N. Kleiman, J. Jackman, I. Sarembock, D. Cohen, D. Spriggs, R. Ebrahimi and 11 more. Journal of the American Medical Association (JAMA), 2003
1,209 citations recorded by the source corpus.
Subfields: Biomedical Engineering, Cardiology and Cardiovascular Medicine, Surgery
View Paper: https://www.semanticscholar.org/paper/1fc24f605248ad93a8a0d1446e894e630c4f64fa
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Cardiology and Cardiovascular Medicine
- Douglas G. Altman
- Rick A. Nishimura
- J. Halperin
- Hani Jneid
- Allan S. Jaffe
- Diana Elbourne
- Karel G. M. Moons
- Gary S. Collins
In Surgery
Citations in the corpus
- 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. (2014, methodology): “If PCI is performed while the patient is on fondaparinux, an additional 85 IU/kg of UFH should be given intravenously immediately before PCI because of the risk of catheter thrombosis (60 IU/kg IV if a GP IIb/IIIa inhibitor used with UFH dosing based on the target-activated clotting time) (27, 157-1”
- Reporting of noninferiority and equivalence randomized trials: an extension of the CONSORT statement. (2006, methodology): “Having demonstrated noninferiority against reference treatment, some authors then make claims for efficacy of a new treatment relative to placebo by also using evidence from earlier trials of reference treatment vs placebo.(46) Such inferences assume assay constancy, ie, current and earlier trials a”
- Guidelines for percutaneous coronary interventions. The Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology. (2005, background): “62, satisfying statistical criteria for superiority of bivalirudin to heparin alone.(291) Patients who received bivalirudin took significantly less time for the ACT to normalize despite significantly higher average ACTs and significantly fewer sub-therapeutic ACTs.”